Conditions of Growth, Economic Analysis - Research Report on Orexigen Therapeutics, Inc. and AVEO Pharmaceuticals, Inc.

Marketwired

HONG KONG--(Marketwire -05/01/12)- Today, www.EquityLeader.com introduced research coverage of Orexigen Therapeutics, Inc. (OREX - News) and AVEO Pharmaceuticals, Inc. (AVEO - News). Full research reports are available to readers at: www.EquityLeader.com/index.php?sm1=OREX&sm2=AVEO.

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Equity Leader has decided to cover Orexigen Therapeutics, Inc. for its current position within the healthcare industry. Orexigen Therapeutics, Inc. (Orexigen) is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Orexigen's combination product candidates focused on obesity are Contrave, which has completed Phase III clinical trials, and Empatic, which has completed Phase II clinical trials. A copy of this report detailing Orexigen Therapeutics, Inc. (OREX - News) is available at: www.EquityLeader.com/index.php?sm1=OREX.

Equity Leader is also taking note of AVEO Pharmaceuticals, Inc. for its changing role within the healthcare industry. AVEO Pharmaceuticals, Inc. (AVEO) is a cancer therapeutics company. The Company focuses on discovering, developing and commercializing targeted cancer therapies to impact patients' lives. The Company's product, Tivozanib, is a potent and selective oral inhibitor of the vascular endothelial growth factor (VEGF), receptors 1, 2 and 3. To download free research on AVEO Pharmaceuticals, Inc. (AVEO - News) investors may visit: www.EquityLeader.com/index.php?sm2=AVEO.

About Equity Leader
Whether you are a first time investor or seasoned market professional, Equity Leader provides the resources necessary to simplify your research process. Our focus has always been to empower investors with the information they need to make their own investment decisions.

Contact:
View Comments (0)